🧪@LorneProteins 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮, 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟰-𝟴
@richberry1983 our VP of biotherapeutics will be providing an overview of our platforms and Senior Scientist @MarcinWegrecki will present data on our oNKo-001 therapy for solid tumors. 2/6
🚨Introducing the new and improved oNKo-innate!
https://t.co/gG6dqkIYa6
Here at oNKo, we’re reshaping the future of #immunooncology 💉🧬🧪
Get to know us better by exploring our new website, and join the immuno-oncology revolution!
#cancertherapy#Immunotherapy
At oNKo-innate, we started out specializing in natural killer cell biology. Since then, we’ve expanded to become Australia’s leading independent #immunooncology company. We’re going through a major rebrand, so watch this space - we’re almost ready to re-introduce ourselves! 🚨
Out in @NatImmunol the latest article from Annemieke de Jong @Columbia in collaboration with @RossjohnLab and colleagues. Here we describe a class of lipid antigens that activate human T cells via CD1a. These T cells expand in people with atopic dermatitis
https://t.co/rQSwSgGy6P
out in @NatureComms the latest article from Ogg Lab in collaboration with @RossjohnLab on CD1a-mediated systemic immune responses in transgenic mice. Impressive amount of work from Clare and colleagues, including identification of new blocking antibodies
https://t.co/SJqny57TzZ
Remembering the first woman to be awarded a Nobel Prize, the first individual to be awarded two Nobel Prizes and still today the only individual with two Nobel Prizes in two different scientific categories: Marie Skłodowska Curie.
Curie was born #OnThisDay in 1867.
BREAKING NEWS:
The 2022 #NobelPrize in Physiology or Medicine has been awarded to Svante Pääbo “for his discoveries concerning the genomes of extinct hominins and human evolution.”